Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash

Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.87B-39.4%
P/S4.3×-3.7×

Profitability

See full
Gross margin97.2%—
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?
Ultragenyx Pharmaceutical (RARE) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of -$1M in Q1 2026.
How has Ultragenyx Pharmaceutical's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?
Ultragenyx Pharmaceutical's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash decreased by 200.0% year-over-year, from $1M to -$1M.